Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SELLAS Life Sciences GroupSLS +4.83%25 Cash-to-Debt is 187.71 as of Jun. 2026, which is 699% above its 10-year median of 23.50. GuruFocus rates SLS with a GF Score™ of 25/100. Among 1,399 Biotechnology companies, SELLAS Life Sciences Group ranks better than 81.2% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. SELLAS Life Sciences Group's cash to debt ratio for the quarter that ended in Jun. 2026 was 187.71.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, SELLAS Life Sciences Groupcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for SELLAS Life Sciences Group's Cash-to-Debt or its related term are showing as below:
SLS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17 Med: 23.5 Max: No Debt
Current: 187.71
During the past 13 years, SELLAS Life Sciences Group's highest Cash to Debt Ratio was No Debt. The lowest was 0.17. And the median was 23.50.
SLS's Cash-to-Debt is ranked better than 81.2% of 1399
companies
in the Biotechnology industry
Industry Median: 6.49
vs SLS: 187.71
SELLAS Life Sciences Group (NAS:SLS) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
SELLAS Life Sciences Group Cash-to-Debt Related Terms
SELLAS Life Sciences Group Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, SELLAS Life Sciences Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group (SLS) has a Cash-to-Debt of 187.71 as of Jun. 2026. This is 699% above median its historical median of 23.50. Over the past decade, SELLAS Life Sciences Group's Cash-to-Debt has ranged from 0.17 to 10,000.00. According to the industry distribution chart, SELLAS Life Sciences Group ranks #263 out of 1399 companies in the Biotechnology industry, placing it in the top 18.8%.
Is SELLAS Life Sciences Group's Cash-to-Debt too high?
SELLAS Life Sciences Group's current Cash-to-Debt of 187.71 is 699% above median its 10-year median of 23.50. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.49. SELLAS Life Sciences Group's value of 187.71 is 2792.3% above this industry median. Based on the distribution chart, SELLAS Life Sciences Group ranks #263 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's Cash-to-Debt compare to IOVA and COAG?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #263 out of 1399 companies for Cash-to-Debt. This places SELLAS Life Sciences Group in the top 19% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 6.49. SELLAS Life Sciences Group's value of 187.71 is 2792.3% above this benchmark. Historically, SELLAS Life Sciences Group's own Cash-to-Debt has ranged from 0.17 to 10,000.00 over the past decade. While the company's 10-year median is 23.50 vs. the industry median of 6.49, SELLAS Life Sciences Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.49, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SELLAS Life Sciences Group's current Cash-to-Debt of 187.71 is 2792.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SELLAS Life Sciences Group's current Cash-to-Debt is 187.71, which is 699% above median its own 10-year median of 23.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current Cash-to-Debt of 187.71. The current Cash-to-Debt is 187.71, which is 699% above median its 10-year median of 23.50 and 2792.3% above the Biotechnology industry median of 6.49. SELLAS Life Sciences Group's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current Cash-to-Debt is 187.71 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score
Get the complete analysis for SLS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLS has been successfully added to your 
